What does the World Health Organization say about CBD?
According to assessments by the World Health Organization (WHO), the substance cannabidiol (CBD) is considered a safe active ingredient. Corresponding legalizations could therefore take place soon.
Autor
Philip Schmiedhofer, MSc
Inhaltsverzeichnis
WHO SAFETY PROFILE FOR CBD
In the expert committee report on drug addiction published by the WHO in November 2017, it is stated that the ingredient cannabidiol has good tolerability
The expert committee report on drug dependence published by WHO in November 2017 shows that the ingredient cannabidiol has good tolerability – provided a good safety profile exists. Scientific findings were used for the analysis to announce an appropriate assessment of therapeutic qualities as well as side effects of CBD. Based on these, it was determined whether cannabis as a medicinal product should be subject to international controls in the future. Test results in both animals and humans concluded generally good tolerability of CBD. The medical treatment of CBD in epileptics has been the most extensively researched so far. According to WHO, however, there is also the possibility of helping other patients with various diseases such as Alzheimer's, Parkinson's, multiple sclerosis, as well as diabetes with cannabis-based medicines.
The published committee report states that cannabidiol, unlike the active ingredient THC (tetrahydrocannabinol), has no addictive properties, no psychoactive effects, and no negative impact on anxiety, heart rate, or even high blood pressure.International bans on pure cannabidiol therefore do not seem justified.
The complete WHO report can be read in full on the following page:
Philip is managing director and co-founder of cannhelp GmbH. With studies in medical engineering and molecular biology, specializing in brain sciences and focusing on cannabinoids, he is recognized as an expert in the use of cannabinoids in medicine. As a medical device consultant, he also leads the sales of cannmedic and offers specialized advice for medical professionals. His expertise includes the development and sales of cannabinoid-based products. In research, he participates in significant basic research at the Centre for Brain Research at the Medical University of Vienna. As co-founder and current managing director of cannmedic GmbH, a pioneer in the trade of CBD medical products, he has many years of entrepreneurial experience. Furthermore, he maintains an extensive network in the field and advises internationally operating companies in the area of medical cannabinoids.
Use the left/right arrows to navigate through the slideshow, or swipe left or right if you are using a mobile device
When you make a selection, a full page will be refreshed.
Press the spacebar and then the arrow keys to make a selection.
